Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women

PHASE3RecruitingINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

June 30, 2028

Study Completion Date

July 31, 2028

Conditions
Recurrent Urinary Tract Infections in Women
Interventions
DRUG

U101

One capsule (100 mg) of U101 will be administered orally three times per day (TID) for 8 weeks followed by one capsule of U101 twice per day (BID) for 16 weeks.

OTHER

Placebo

One capsule of Placebo will be administered orally three times per day (TID) for 8 weeks followed by one capsule of placebo twice per day (BID) for 16 weeks.

Trial Locations (13)

Unknown

RECRUITING

Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung City

ACTIVE_NOT_RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

RECRUITING

Taipei Tzu Chi Hospital, New Taipei City

RECRUITING

China Medical University Hospital, Taichung

RECRUITING

Chung Shan Medical University Hospital, Taichung

RECRUITING

Taichung Veterans General Hospital, Taichung

RECRUITING

National Cheng Kung University Hospital, Tainan City

RECRUITING

Chang Gung Memorial Hospital, Taipei Branch, Taipei

RECRUITING

National Taiwan University Hospital, Taipei

RECRUITING

Taipei Medical University Hospital, Taipei

RECRUITING

Taipei Veterans General Hospital, Taipei

RECRUITING

Tri-Service General Hospital (TSGH), Taipei

RECRUITING

Chang Gung Memorial Hospital, Linkuo Branch, Taoyuan District

All Listed Sponsors
lead

TCM Biotech International Corp.

INDUSTRY

NCT07184827 - Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women | Biotech Hunter | Biotech Hunter